NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics

Dateline City:

SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.

Partnership Combines NGM’s Unique Biology-focused Research Platform with Merck’s Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases

SOUTH SAN FRANCISCO, Calif. & KENILWORTH, N.J.--(BUSINESS WIRE)--
NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced they have entered into a multi-year collaboration to
research, discover, develop and commercialize novel biologic therapies
across a wide range of therapeutic areas. This agreement will become
effective upon the expiration of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act.

Language:

English

Contact:

MerckMedia Relations:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestor Relations:Justin Holko, 908-740-1879orNGM BiopharmaceuticalsMedia Relations:Tony Plohoros, 908-940-01356 [e-mail] Relations:Beth DelGiacco, 212-362-1200Stern Investor [e-mail]

...

Source: Merck.com - Corporate News - February 23, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news